AstraZeneca and Bristol-Myers Squibb are in discussions about a potential merger, which could create a combined company valued at nearly $400 billion, making it one of the largest pharmaceutical firms globally. AstraZeneca has a market capitalization of approximately $264 billion, while Bristol-Myers Squibb stands around $133 billion. Although talks have been ongoing, there is speculation that they could stall or fail. Recently, both companies reported strong second-quarter earnings, with Bristol-Myers showing significant stock gains over the past year, aided by successful Q2 results. Regulatory challenges are anticipated due to the scale of the merger, requiring scrutiny from various competition authorities. Both companies will release their Q3 results in late October, potentially affecting market perceptions and merger discussions.

Oops, something went wrong

Skip to navigation Skip to main content Skip to right column

AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report

Rachael Rajan

Sun, August 2, 2026 at 5:14 PM EDT3 min read

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report.

A combined entity would carry a value of nearly $400 billion, which would rank it among the world's largest pharmaceutical groups. AstraZeneca holds a market capitalisation of approximately $264 billion, while Bristol Myers Squibb adds roughly $133 billion.

The FT, citing people familiar with the matter, said the discussions took place over recent months but cautioned that talks could be delayed or fall apart entirely. No deal structure has been disclosed, and neither company provided comments or shared a statement.

AstraZeneca's NYSE-listed shares ended Friday's session at $169.64, down $1.70 on the day, and sit more than $40 below their 52-week high of $212.71. Bristol Myers Squibb, meanwhile, closed Friday at $65.31, a whisker from its own 52-week high of $65.66 printed intraday on above-average volume of 14.58 million shares.

BMY has gained roughly 47.7% over the past year, driven in part by a strong second quarter: the company reported Q2 2026 EPS of $2.04, beating consensus of $1.61, on revenue of $12.97 billion, topping estimates of $11.71B.

AstraZeneca also delivered a solid Q2, posting EPS of $2.63 against a $2.48 estimate on revenue of $15.38 billion versus consensus estimates of $15.45B on July 27.

Under CEO Pascal Soriot, the company successfully rebuffed a $118 billion takeover approach from Pfizer in 2014, and its share price has more than quadrupled in the years since. More recently, AstraZeneca announced a $50 billion U.S. manufacturing and R&D investment commitment and outlined plans for a direct U.S. listing, a move designed to capture stronger American equity valuations. How a merger with BMY fits alongside those ambitions would need to be addressed by management.

Bristol Myers Squibb, meanwhile, has pursued acquisitions to reinvigorate a pipeline under pressure from patent cliffs, with GAAP R&D spending falling roughly 11% to approximately $10 billion in 2025. Its oncology and immunology assets, including partnership agreements with BioNTech and Hengrui Pharma, have helped underpin the stock's rally, but a larger platform could accelerate pipeline diversification.

Regulatory complexity would be formidable. A cross-border combination of this scale would draw scrutiny from the U.S. Federal Trade Commission, the UK Competition and Markets Authority, and the European Commission simultaneously.

Story Continues

Investors will get their next formal look at both companies in late October. Bristol Myers Squibb is scheduled to report Q3 2026 results on October 29, with consensus pointing to EPS of $1.61 on revenue of $12.04 billion. AstraZeneca follows on October 30, where consensus EPS stands at $2.63 on revenue of $16.06 billion. Any deal announcement before those dates would likely pre-empt or significantly reshape guidance conversations on both calls. Monday's open will offer the first real read on how markets are pricing the odds.

AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report

Wolfe Research outlines eight risks that could spark stock declines in 2026

This sector is 'poised for a big, beautiful year': Truist

View Comments

Terms and Privacy Policy

Your Privacy Choices

More Info

Read Original at Yahoo Finance →